Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ: EVO )

9.830 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 Next >
Evotec and Novo Nordisk Launch LAB eN² to Accelerate Translation in Cardiometabolic Diseases
Via ACCESSWIRE
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
Via ACCESSWIRE
Evotec SE Reports First Half-Year 2023 Results on 29 August 2023
Via ACCESSWIRE
Evotec Provides Update on Financial Impact of Cyber-Attack
Via ACCESSWIRE
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
Via ACCESSWIRE
Evotec SE Provides Update on Cyber Attack
Via ACCESSWIRE
Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program
Via ACCESSWIRE
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
Via ACCESSWIRE
Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items
Via ACCESSWIRE
Evotec Presents Sustainability Strategy
Via ACCESSWIRE
Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
Via ACCESSWIRE
Just - Evotec Biologics Enters Strategic Biosimilars Partnership with Sandoz
Via ACCESSWIRE
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
Via ACCESSWIRE
Cyber Attack on Evotec
Via ACCESSWIRE
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
Via ACCESSWIRE
Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
Via ACCESSWIRE
Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
Via ACCESSWIRE
Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023
Via ACCESSWIRE
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Sernova Corp. (TSX: SVA) Featured in Coverage of the 35th Annual Roth Conference
Via Investor Brand Network
Evotec Receives € 150 m Loan from European Investment Bank
Via ACCESSWIRE
Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership
Via ACCESSWIRE
Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
Via ACCESSWIRE
Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies
Via ACCESSWIRE
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
Via ACCESSWIRE
Evotec SE Reports Results for the First Nine Months 2022 and Provides Corporate Update
Via ACCESSWIRE
Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022
Via ACCESSWIRE
Evotec Completes Acquisition of Central Glass Germany
Via ACCESSWIRE
Evotec Presents Paradigm Shift in Biologics at Capital Markets Day
Via ACCESSWIRE
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions
Via ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.